Coherus Oncology, Inc. (CHRS) stock
CHRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 6/3038% below fair value
$0.53−0.01 (-2.41%)
Close on Nov 13, 2026Market cap $81.19MP/E –Yield –
Coherus Oncology profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Coherus Oncology's profit margin for the twelve months ending Sep 30, 2026 was -253.4%. For fiscal 2025 it was 398.4%, against 108.0% the year before. The highest annual figure on record is 398.4% in fiscal 2025.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 398.4% | +290.4 |
| FY2024 | Dec 31, 2024 | 108.0% | +200.5 |
| FY2023 | Dec 31, 2023 | -92.5% | +45.8 |
| FY2022 | Dec 31, 2022 | -138.2% | −50.3 |
| FY2021 | Dec 31, 2021 | -87.9% | −115.7 |
| FY2020 | Dec 31, 2020 | 27.8% | +2.6 |
| FY2019 | Dec 31, 2019 | 25.2% | +15331.8 |
| FY2017 | Dec 31, 2017 | -15306.6% | −15239.6 |
| FY2016 | Dec 31, 2016 | -67.0% | +676.2 |
| FY2015 | Dec 31, 2015 | -743.2% | −463.1 |
| FY2014 | Dec 31, 2014 | -280.1% | +1669.5 |
| FY2013 | Dec 31, 2013 | -1949.7% | −211.0 |
| FY2012 | Dec 31, 2012 | -1738.7% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -275.6% | +31.5 |
| Q2 FY2026 | Jun 30, 2026 | -144.2% | −3048.1 |
| Q1 FY2026 | Mar 31, 2026 | -311.3% | +433.1 |
| Q4 FY2025 | Dec 31, 2025 | -295.3% | +360.3 |
| Q3 FY2025 | Sep 30, 2025 | -307.1% | −129.4 |
| Q2 FY2025 | Jun 30, 2025 | 2903.9% | +3029.4 |
| Q1 FY2025 | Mar 31, 2025 | -744.4% | −5201.7 |
| Q4 FY2024 | Dec 31, 2024 | -655.6% | −568.6 |
| Q3 FY2024 | Sep 30, 2024 | -177.6% | −124.5 |
| Q2 FY2024 | Jun 30, 2024 | -125.5% | −52.5 |
| Q1 FY2024 | Mar 31, 2024 | 4457.3% | +4690.8 |
| Q4 FY2023 | Dec 31, 2023 | -87.0% | +42.8 |
| Q3 FY2023 | Sep 30, 2023 | -53.2% | +137.6 |
| Q2 FY2023 | Jun 30, 2023 | -73.0% | +10.4 |
| Q1 FY2023 | Mar 31, 2023 | -233.5% | −73.6 |
| Q4 FY2022 | Dec 31, 2022 | -129.8% | −67.5 |
| Q3 FY2022 | Sep 30, 2022 | -190.8% | −144.1 |
| Q2 FY2022 | Jun 30, 2022 | -83.4% | −49.3 |
| Q1 FY2022 | Mar 31, 2022 | -159.8% | +48.5 |
| Q4 FY2021 | Dec 31, 2021 | -62.3% | −71.1 |
| Q3 FY2021 | Sep 30, 2021 | -46.7% | −71.3 |
| Q2 FY2021 | Jun 30, 2021 | -34.1% | −77.6 |
| Q1 FY2021 | Mar 31, 2021 | -208.3% | −238.9 |
| Q4 FY2020 | Dec 31, 2020 | 8.8% | −22.9 |
| Q3 FY2020 | Sep 30, 2020 | 24.6% | −17.5 |
| Q2 FY2020 | Jun 30, 2020 | 43.5% | +15.3 |
| Q1 FY2020 | Mar 31, 2020 | 30.6% | +84.5 |
| Q4 FY2019 | Dec 31, 2019 | 31.7% | +3998.4 |
| Q3 FY2019 | Sep 30, 2019 | 42.1% | +46488.1 |
| Q2 FY2019 | Jun 30, 2019 | 28.2% | +9023.6 |
| Q1 FY2019 | Mar 31, 2019 | -53.9% | – |
| Q2 FY2017 | Jun 30, 2017 | -3966.7% | – |
| Q1 FY2017 | Mar 31, 2017 | -46446.0% | – |
| Q4 FY2016 | Dec 31, 2016 | -8995.4% | – |
See a number that looks wrong?